Epizyme Revenue 2012-2022 | EPZM

Epizyme revenue from 2012 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Epizyme Annual Revenue
(Millions of US $)
2021 $37
2020 $16
2019 $24
2018 $22
2017 $10
2016 $8
2015 $3
2014 $41
2013 $68
2012 $45
2011 $7
Epizyme Quarterly Revenue
(Millions of US $)
2022-03-31 $9
2021-12-31 $12
2021-09-30 $5
2021-06-30 $13
2021-03-31 $8
2020-12-31 $8
2020-09-30 $4
2020-06-30 $2
2020-03-31 $1
2019-12-31 $4
2019-09-30 $6
2019-06-30 $6
2019-03-31 $8
2018-12-31 $10
2018-09-30
2018-06-30 $12
2018-03-31
2017-12-31
2017-09-30
2017-06-30 $10
2017-03-31
2016-12-31 $0
2016-09-30 $7
2016-06-30 $0
2016-03-31 $0
2015-12-31 $1
2015-09-30 $0
2015-06-30 $1
2015-03-31 $1
2014-12-31 $10
2014-09-30 $8
2014-06-30 $9
2014-03-31 $13
2013-12-31 $36
2013-09-30 $8
2013-06-30 $15
2013-03-31 $9
2012-12-31
2012-09-30 $15
2012-06-30 $15
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.087B $0.037B
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Biohaven Pharmaceutical Holding (BHVN) United States $9.948B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Emergent Biosolutions (EBS) United States $1.592B 6.82
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.00
SQZ Biotechnologies (SQZ) United States $0.092B 0.00